Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Glycopyrrolate oral - Shionogi

Drug Profile

Glycopyrrolate oral - Shionogi

Alternative Names: Cuvposa; FHPC 02; Glycopyrrone bromide; Glycopyrronium bromide; Oral glycopyrrolate liquid

Latest Information Update: 20 Dec 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Wyeth
  • Developer Medexus Pharmaceuticals; Shionogi Pharma
  • Class Antiasthmatics; Antispasmodics; Antiulcers; Pyrrolidines; Quaternary ammonium compounds; Skin disorder therapies; Small molecules
  • Mechanism of Action Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sialorrhoea
  • New Molecular Entity No

Highest Development Phases

  • Marketed Sialorrhoea

Most Recent Events

  • 13 Dec 2018 Pediapharm is now called Medexus Pharmaceuticals
  • 03 Apr 2018 Launched for Sialorrhoea (In adolescents, In children) in Canada (PO)
  • 27 Nov 2017 Pediapharm intends to launch Glycopyrrolate oral in Canada in first quarter of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top